The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer

被引:227
作者
Nachmias, B [1 ]
Ashhab, Y [1 ]
Ben-Yehuda, D [1 ]
机构
[1] Hadassah Univ Hosp, Dept Hematol, IL-91120 Jerusalem, Israel
关键词
apoptosis; cancer; IAP; caspase; molecular targets;
D O I
10.1016/j.semcancer.2004.04.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Apoptosis is a crucial biological process that prevents uncontrolled cell proliferation and eliminates harmful cells. Resistance to apoptotic stimuli is a hallmark feature of various cancers. One of the mechanisms through which tumor cells are believed to acquire resistance to apoptosis is by overexpression of inhibitor of apoptosis proteins (IAPs). IAPs are a group of structurally related proteins that were initially identified in baculoviruses. Mammalian IAPs block apoptosis either by binding and inhibiting caspases or through caspase-independent mechanisms. This family of proteins has become increasingly prominent in the field of cancer biology. To date, overexpression of several IAPs has been detected in various cancers. This paper reviews the recent advances in the research of IAPs. The differential expression and the biological significance of each IAP in various cancer types will be discussed. Finally, we review the most recent advances in the research efforts aimed at using IAPs as potential targets for cancer therapy. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:231 / 243
页数:13
相关论文
共 145 条
[91]   Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract [J].
Nakanishi, K ;
Tominaga, S ;
Hiroi, S ;
Kawai, T ;
Aida, S ;
Kasamatsu, H ;
Aurues, T ;
Hayashi, T ;
Ikeda, T .
VIRCHOWS ARCHIV, 2002, 441 (06) :559-563
[92]   Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2 [J].
Nishihara, H ;
Kizaka-Kondoh, S ;
Insel, PA ;
Eckmann, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (15) :8921-8926
[93]  
Notarbartolo M, 2004, ONCOL REP, V11, P133
[94]   A p34cdc2 survival checkpoint in cancer [J].
O'Connor, DS ;
Wall, NR ;
Porter, ACG ;
Altieri, DC .
CANCER CELL, 2002, 2 (01) :43-54
[95]   Survivin and aven: two distinct antiapoptotic signals in acute leukemias [J].
Paydas, S ;
Tanriverdi, K ;
Yavuz, S ;
Disel, U ;
Sahin, B ;
Burgut, R .
ANNALS OF ONCOLOGY, 2003, 14 (07) :1045-1050
[96]  
PENNATI M, 2004, SERCINOGENESIS
[97]   Pathways of apoptosis in lymphocyte development, homeostasis, and disease [J].
Rathmell, JC ;
Thompson, CB .
CELL, 2002, 109 :S97-S107
[98]   Apoptosis and cancer: Strategies for integrating programmed cell death [J].
Reed, JC .
SEMINARS IN HEMATOLOGY, 2000, 37 (04) :9-16
[99]   Hla-B35-restricted immune responses against survivin in cancer patients [J].
Reker, S ;
Becker, JC ;
Svane, IM ;
Ralfkiaer, E ;
Straten, PT ;
Andersen, MH .
INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (06) :937-941
[100]  
REKER S, 2004, CANCER BIOL THER, P3